JP2023542257A5 - - Google Patents

Info

Publication number
JP2023542257A5
JP2023542257A5 JP2023541485A JP2023541485A JP2023542257A5 JP 2023542257 A5 JP2023542257 A5 JP 2023542257A5 JP 2023541485 A JP2023541485 A JP 2023541485A JP 2023541485 A JP2023541485 A JP 2023541485A JP 2023542257 A5 JP2023542257 A5 JP 2023542257A5
Authority
JP
Japan
Prior art keywords
composition
days
sequence
approximately
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023541485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542257A (ja
JP7828349B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050546 external-priority patent/WO2022060901A1/en
Publication of JP2023542257A publication Critical patent/JP2023542257A/ja
Publication of JP2023542257A5 publication Critical patent/JP2023542257A5/ja
Priority to JP2025203927A priority Critical patent/JP2026032147A/ja
Application granted granted Critical
Publication of JP7828349B2 publication Critical patent/JP7828349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023541485A 2020-09-16 2021-09-15 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法 Active JP7828349B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203927A JP2026032147A (ja) 2020-09-16 2025-11-26 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079418P 2020-09-16 2020-09-16
US63/079,418 2020-09-16
PCT/US2021/050546 WO2022060901A1 (en) 2020-09-16 2021-09-15 Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203927A Division JP2026032147A (ja) 2020-09-16 2025-11-26 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法

Publications (3)

Publication Number Publication Date
JP2023542257A JP2023542257A (ja) 2023-10-05
JP2023542257A5 true JP2023542257A5 (https=) 2024-09-24
JP7828349B2 JP7828349B2 (ja) 2026-03-11

Family

ID=78135143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023541485A Active JP7828349B2 (ja) 2020-09-16 2021-09-15 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法
JP2025203927A Pending JP2026032147A (ja) 2020-09-16 2025-11-26 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203927A Pending JP2026032147A (ja) 2020-09-16 2025-11-26 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法

Country Status (9)

Country Link
US (1) US20230398147A1 (https=)
EP (1) EP4214233A1 (https=)
JP (2) JP7828349B2 (https=)
CN (1) CN116829183A (https=)
AU (1) AU2021345124A1 (https=)
CA (1) CA3194771A1 (https=)
MX (1) MX2023003041A (https=)
TW (1) TW202222823A (https=)
WO (1) WO2022060901A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008870A2 (pt) 2019-08-12 2021-11-30 Abl Bio Inc Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
LT3819007T (lt) * 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
JP2025516805A (ja) * 2022-05-20 2025-05-30 アイ-エムエービー バイオファーマ ユーエス リミテッド 固形腫瘍を治療する方法
TW202415407A (zh) * 2022-06-30 2024-04-16 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗cldn18.2抗體的藥物製劑
CN118667026A (zh) 2023-03-15 2024-09-20 三生国健药业(上海)股份有限公司 抗muc17*cd3*cd28三特异性抗体
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
EP2172483A4 (en) 2007-07-04 2010-08-04 Forerunner Pharma Res Co Ltd ANTI-MUC17 ANTIBODY
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
KR101695327B1 (ko) 2008-11-07 2017-01-11 암젠 리서치 (뮌헨) 게엠베하 급성 림프구성 백혈병의 치료방법
RS54655B2 (sr) * 2009-10-27 2021-04-29 Amgen Res Munich Gmbh Dozni režim za primenu cd19xcd3 bispecifičnog antitela
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
MX353382B (es) 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーBioNTech AG クローディンを発現するガン疾患を処置するための剤
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
PL2970449T3 (pl) 2013-03-15 2020-04-30 Amgen Research (Munich) Gmbh Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
RU2016132863A (ru) 2014-01-15 2018-02-20 Займворкс Инк. БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
KR20250175345A (ko) 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
SMT202500367T1 (it) 2017-02-02 2025-11-10 Amgen Res Munich Gmbh Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
JP2020536969A (ja) * 2017-10-12 2020-12-17 アンフィヴェナ セラピューティクス,インク. Cd3結合タンパク質の投薬レジメン
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3710478A1 (en) 2017-11-13 2020-09-23 Crescendo Biologics Limited Molecules that bind to cd137 and psma
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對muc17和cd3之雙特異性抗體構建體
BR112020017053A2 (pt) 2018-02-21 2020-12-15 Celgene Corporation Anticorpos que se ligam ao bcma e usos dos mesmos
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3101271A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
PE20211916A1 (es) 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
WO2020025792A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020072306A1 (en) * 2018-10-01 2020-04-09 Amgen Inc. Methods for reducing aggregation of bispecific antibodies

Similar Documents

Publication Publication Date Title
JP2023542257A5 (https=)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
JP2021528973A5 (https=)
JP2025138634A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP2020516240A5 (https=)
JP2020504723A5 (https=)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2024541680A5 (https=)
JP2021523122A5 (https=)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2023542290A5 (https=)
JP2023542289A5 (https=)
JP2025032102A5 (https=)
JP2023541858A5 (https=)
JP2023532129A5 (https=)
JP2022540083A5 (https=)
JP2017534646A5 (https=)
JP2021512107A5 (https=)
JP2025026572A5 (https=)
JP2017534645A5 (https=)
JP2018535961A5 (https=)
CN101657215A (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
JP2022528005A5 (https=)
JP2023548529A5 (https=)
JP2024534602A5 (https=)